Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-01-31
2006-01-31
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
active
06992110
ABSTRACT:
The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
REFERENCES:
patent: 4478836 (1984-10-01), Mouzin
patent: 5034541 (1991-07-01), Bigg
patent: 5621142 (1997-04-01), Mochizuki
patent: 6395788 (2002-05-01), Iglehart, III
patent: 6441038 (2002-08-01), Loder et al.
patent: 0 759 299 (2000-04-01), None
patent: 2 752 732 (1998-03-01), None
patent: WO 95/22521 (1995-08-01), None
patent: WO 97/35574 (1997-10-01), None
patent: WO 97/35584 (1997-10-01), None
patent: WO 98/08495 (1998-03-01), None
patent: WO 98/36744 (1998-08-01), None
patent: WO 99/59593 (1999-11-01), None
patent: WO 01/26623 (2001-04-01), None
patent: WO 00/32178 (2002-06-01), None
patent: WO 02/053140 (2002-07-01), None
DRUGU AN 1992-39596, Moreau, G et al, Fundam.Clin.Pharmacol. 6 (4-5) 226, 1992, abstract.
DRUGU AN 1983-01770, Woerz zum Thema R, Muench.Med.Wochenschr. 124 (40) 855-56, 1982, abstract.
EMBASE AN 1998129084, Prescrire Enternational, 1998, 7/34, 51-53, abstract.
EMBASE AN 90228858, Macher J et al, Neuropsychobiology, 1989, 22/2, 77-82, abstract.
Ardid, et al., “Antidepressants and pain,” La Lettre de Pharmacologue 13: 8 (1993).
Cypress Bioscience, Inc., Investor Fact Sheet, Aug. 2001.
Dryson, “Venflaxine and fibromyalgia,” NZ Med. J. 113(1105): 87 (2000).
Nagaoka, et al., “Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a case report,” Med. Drug. J. 37: 10 (2001).
Noguchi, et al., “Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and their protective effect against NMDA-induced neurotoxicity,” Synapse 31: 87-96 (1999).
Shuto, et al., “±-Z-2-(Aminomethyl)-1-phenlcyclopropanecarboximide derivatives as a new prototype of NMDA receptor antagonists,” J. Med. Chem. 38: 2964-2968 (1995).
Shuto, et al., “(1S,2R)-1-(phenyl-2-[(s)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC), a new class of NMDA-receptor antagonist: molecular design by a novel conformational restriction strategy,” Jpn. J. Pharmacol. 85: 207-213 (2001).
Shuto, et al., “Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-[phenyl-2-[(S)]-1aminoprophyl]-N,N-diethylcyclopropanecarboxamide, an efficient noncompetitive N-methyl-D-aspartic acid receptor antagonist,”J. Med. Chem.39: 4844-4852 (1996).
Shuto, et al., “Synthesis and biological activity of conformationally restricted analogues of milnacipran: (1S,2R)-1-phenyl-2-[(r)-1-amino-2-propynyl]-N,N-diethylcyclopropane-carboximide is a novel class of NMDA receptor channel blocker,” J. Med. Chem. 41: 3507-3514 (1998).
Rao et al., The neuropharmacology of centrally-acting analgesic medications in fibromyalgia,Theum. Dis. Clin. N. Am.28 (2002) 235-259.
Ninan, M.D., Philip T., Use of Venlafaxine in Other Psychiatric Disorders,Depression and Anxiety12(1) (2000) 90-94.
Nutt et al., Potential Applications of Venlafaxine,Rev. Contemp. Pharmacother.9 (1998) 321-331.
Dwight et al., An Open Clinical Trial of Venlafaxine Treatment of Fibromyalgia,Psychsomatics39(1) (1998) 14-17.
Goodnick et al., Psychotropic Treatment of Chronic Fatigue Syndrome and Related Disorders,J. Clin, Psychiatry54(1) (1993) 13-20.
Kranzler Jay D.
Rao Srinivas G.
Cook Rebecca
Cypress Bioscience, Inc.
Darby & Darby
LandOfFree
Methods of treating fibromyalgia syndrome, chronic fatigue... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating fibromyalgia syndrome, chronic fatigue..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating fibromyalgia syndrome, chronic fatigue... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3542347